Phase I trial of nedaplatin and paclitaxel for patients with non-small cell lung cancer

Journal of Chemotherapy

Volumn 17, Issue 5, 2005, Pages 550-554

  Yoshiike, F ^a   Koizumi, Tomonobu ^a   Kitaguchi, Y ^a   Hatayama, O ^a   Yasuo, M ^a   Sasabayashi, M ^a   Wakamatsu, H ^a   Fujimoto, K ^a   Kubo, K ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Nedaplatin; Neutropenia; New generation platinum compound; Non small cell lung cancer; Thrombocytopenia

Indexed keywords

CARBOPLATIN; CHLORPHENIRAMINE; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; IRINOTECAN; NEDAPLATIN; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ARTHRITIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 28144442215     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.5.550     Document Type: Article

References (18)

1. Shiratori O, Kasai H, Uchida N, et al. Anti-tumor activity of 254-S, a platinum complex, in rodents. In: Ishigami J (Ed.), Recent Advances in Chemotherapy, University of Tokyo Press, Tokyo, 1985: 635-636.
2. Kameyama Y, Okazaki N, Nakagawa M, et al. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990; 52(1): 15-24.
3. Koenuma M, Kasai H, Uchida N, et al. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell cancers of cis-diammineglycolatoplatinum (254-S) and cisdiamminedichloroplatinum. Anticancer Res 1995; 15(2): 417-421.
4. Fukuda M, Shinkai T, Eguchi F, et al. Phase II study of (glycolate-O,O') diammine platinum (II), a novel platinum complex, in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1990; 26(6): 393-396.
5. Furuse K, Fukuoka M, Kurita Y, et al. A phase II clinical study of cis diammine glycolato platinum, 254-S, for primary lung cancer. Jpn J Cancer Chemother 1992; 19(6): 879-884. (Japanese)
6. Hirose T, Horichi N, Ohmori T, et al. Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung Cancer 2003; 39(1): 91-97.
7. Kurata T, Tamura K, Yamamoto N, et al. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 2004; 90 (11): 2092-2096.
8. Oshita F, Yamada K, Kato Y, et al. Phase I/II study of escalating of nedaplatin in combination with irinotecan for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2003; 52(1): 73-78.
9. Oshita F, Yamada K, Saito H, et al. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J Exp Ther Oncol 2004; 4(4): 343-348.
10. Tsuda H, Hashiguchi Y, Nishimura S, et al. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 2004; 91(6): 1032-1037.
11. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. For the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002; 346(2): 92-98.
12. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19(13): 3210-3218.
13. Takigawa N, Segawa Y, Ueoka H, et al. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small cell lung cancer. Cancer Chemother Pharmacol 2000; 46(4): 272-278.
14. Å@Alberts DS, Fanta PT, Running KL, et al. In vitro Phase II comparison of the cytotoxicity of a novel platinum analog, nedapatin (254-S), with that of cisplatin and carboplatin against fresh human ovarian cancers. Cancer Chemother Pharmacol 1997; 39(6): 493-497.
15. Å@Yamada H, Uchida N, Maekawa R, et al. Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 2001; 172(1): 17-25.
16. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13(10): 1539-1549.
17. Sekine I, Nokihara H, Horiike A, et al. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Br J Cancer 2004; 90(6): 1125-1128.
18. Koizuimi T, Kubo K, Shinozaki S, et al. Pharmacokinetic evaluation of (glycolao-O,O') diammine platinum (II) in lung lymph in sheep. Jpn J Cancer Res 1993; 84(4): 468-473.